[A16-32] Elotuzumab - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2016
Commission awarded on 01.06.2016 by the Federal Joint Committee (G-BA).
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-80||Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A16-66||Elotuzumab (multiple myeloma) - Addendum to Commission A16-32||Commission completed|
|A21-90||Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)||Commission completed|